X4 Pharmaceuticals (XFOR) Q2 2024 earnings summary

Executive summary

• Achieved FDA approval and U.S. commercial launch of XOLREMDI (mavorixafor) for WHIM syndrome in April 2024, marking a major milestone in rare disease treatment and the company's first commercial product launch.

• Full commercial team deployed; initial patients treated, with positive feedback on patient support and reimbursement processes.

• Significant progress in expanding mavorixafor's use to chronic neutropenia (CN), with positive interim Phase 2 data announced in June 2024 and initiation of a global Phase 3 (4WARD) trial.

• Preparing for regulatory submissions in Europe by early 2025.

Financial highlights

• Net income for Q2 2024 was $90.8 million, compared to a net loss of $55.7 million in Q2 2023, driven by a $105 million gain on the sale of a priority review voucher and a $20.2 million non-cash gain on warrant remeasurement.

• Product revenue, net, was $0.6 million and cost of revenue was $0.3 million for Q2 2024, the first period with product sales.

• R&D expenses were $20.9 million (up from $15.6 million YoY); SG&A expenses were $13.3 million (up from $10.2 million YoY), both including $1.2 million in non-cash expenses.

• Cash, cash equivalents, and marketable securities totaled $169.5 million as of June 30, 2024.

Outlook and guidance

• Sufficient funds to support operations into late 2025, excluding future XOLREMDI revenue; additional capital may be required beyond 12 months.

• Full Phase 2 CN data to be presented in November 2024; Phase 3 FORWARD trial enrollment on track for mid-2025 completion.

• MAA submission to the European Medicines Agency for mavorixafor in WHIM syndrome expected by early 2025.

• Sales guidance for XOLREMDI to be provided at a future date.